Revision history
Back to the articleThese are preserved drafts. Earlier evidence may have changed; use the current reading to check availability.
Revision 1 · Elotuzumab regimens showed mixed side-effect risks
Saved 2026-09-15 · Not clinically reviewed
Read this saved revision and its sources
A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences. The analysis compared elotuzumab-containing regimens, not elotuzumab alone; longer treatment and corticosteroid use may have influenced differences, so effects cannot be assigned solely to elotuzumab. Higher risks included pneumonia, diarrhea and infections; grade 3-4 lymphopenia, diarrhea, pneumonia, cataracts and infections were also increased.
A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences.
What the study found
A systematic review pooled randomized trials comparing elotuzumab-containing regimens with control therapies in multiple myeloma. The elotuzumab regimens had higher risks of pneumonia, diarrhea and infections, but lower neutropenia. Higher-grade lymphopenia, diarrhea, pneumonia, cataracts and infections were also more common; however, longer treatment and corticosteroid use may have influenced some differences.
Elotuzumab-containing regimens had higher pneumonia risk, with a relative risk of 1.30 and a 95% confidence interval of 1.07-1.59, while neutropenia was less frequent.
Who and what was studied
People with multiple myeloma enrolled in 6 randomized controlled trials, totaling 1,736 participants.
Elotuzumab-containing regimens were compared with control therapies.
What remains uncertain
The analysis compared elotuzumab-containing regimens, not elotuzumab alone; longer treatment and corticosteroid use may have influenced differences, so effects cannot be assigned solely to elotuzumab. Higher risks included pneumonia, diarrhea and infections; grade 3-4 lymphopenia, diarrhea, pneumonia, cataracts and infections were also increased.
Which parts of this research are relevant to the questions I should discuss with my care team?